premium price-to-earnings downgrad under-perform
net dbt
mani uncertainti think stock lag
downgrad share buy under-perform
lower price object view base expect
signific downsid rather on-going industry-wid uncertainti warrant
signific premium vs group also view recent challeng seen
walgreen abc largest custom drive potenti increment volume/revenu
slowdown margin pressur particularli increment benefit wbad
gener sourc group slow reduc ep
ep new price object repres
ep estim still target multipl cardin health
recent challeng seen across broader pharma suppli chain compani
creat on-going question futur profit growth sector whether
pharmaci reimburs lower gener sourc save public pressur reduc drug
price number area entir drug channel remain somewhat
inflat balloon one side push pushback creat pressur
anoth side case rest drug distributor broad-bas
pressur pharmaci reimburs like exacerb current state
distributor sell-side pressur challeng sourc benefit moder
pharmedium compound busi drag profit sinc
potenti much headwind expect low end
guidanc lengthi delay reopen memphi drive volum headwind
manag work ring fenc oper headwind uncertainti still
creat question non-pharma profit growth meanwhil mwi remain mostli steadi
although saw flat revenu growth ebit expect recent
quarter similar result seen last quarter own
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
one largest drug distributor us
sizabl global gener sourc joint ventur
partnership
anim health unit oper
companion product anim distribut
transport logist technolog
compani base chesterbrook pa
under-perform rate driven uncertainti
on-going pharmedium closur creat
addit margin drag see concern
profit squeez across pharma suppli chain
subsector would expect distributor like
whose pharmaci struggl
reimburs pressur feel
squeez addit expect
continu premium cah/mck see
spread close
reduc estim account industri pressur
account pressur seen across market concern increment
headwind hit drug distributor particularli regard pharmaci purchas
pressur reduc estim across board reduc
ep ep expect
pressur felt custom price on-going headwind vs current year
creat elev pressur beyond
increment profit headwind expect see could overli pessimist
biggest risk new under-perform rate would closer align
walgreen includ potenti acquisit walgreen current own
abc outstand share part two compani long-term partnership form
previou press report potenti acquisit
walgreen manag even ask potenti april earn call
note consist evalu wide rang opportun creat valu
said walgreen distinctli focus pursu partnership model
rather sizabl acquisit creat allianc compani
labcorp other addit think biggest
issu plagu walgreen primarili around reimburs pressur
store base current posit drive profit reacceler
believ hypothet acquisit would solv issu
off-set compani reimburs headwind wba/abc alreadi benefit jointli
sourc gener drug fix current front end challeng face wba
almost store event pursu larg acquisit rather
partnership model current bet see better strateg fit
valuat warrant vs cah/mck question much
consist trade premium two
closest peer attribut premium outsiz specialti busi compar
two faster growth increment contribut busi mwi
relationship walgreen think reason
creat least delta valuat think magnitud delta rel
histor level wider deserv given multitud uncertainti current
impact group whole
exhibit rel valuat steadi recent premium still elev vs cah/mck
chart forward price-to-earnings premium near highest level last year
price object base ep multipl
five-year averag five-year high although would argu
artifici high due period gener inflat also repres bigger
discount vs last five year think discount warrant given
incorpor modest growth slowdown seen rest suppli
chain well encompass competit risk
upsid risk po potenti volum pickup increas buyside/sellsid
spread opportun cost save deepen relationship
walgreen largest custom downsid risk po increment wors
drug price pressur increas competit creat gross profit headwind risk
amazon anoth disrupt forc enter suppli chain market lack avail
attract capit deploy opportun uncertainti across market
michael cherni herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
